Capital Research Global Investors 13D and 13G filings for Allogene Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-11 12:22 pm Sale | 2022-02-14 | 13G | Allogene Therapeutics, Inc. ALLO | Capital Research Global Investors | 0 0.000% | -12,640,338 (Position Closed) | Filing |
| 2021-02-16 3:46 pm Purchase | 2021-02-16 | 13G | Allogene Therapeutics, Inc. ALLO | Capital Research Global Investors | 12,640,338 9.000% | 6,097,660 (+93.20%) | Filing |